Inogen, Inc. (NASDAQ:INGN - Get Free Report) saw a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 714,200 shares, a decrease of 6.2% from the December 15th total of 761,300 shares. Based on an average trading volume of 187,000 shares, the days-to-cover ratio is presently 3.8 days.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Inogen by 312.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company's stock worth $1,694,000 after acquiring an additional 132,287 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Inogen by 2.7% in the third quarter. JPMorgan Chase & Co. now owns 896,106 shares of the medical technology company's stock worth $8,692,000 after purchasing an additional 23,891 shares during the period. Barclays PLC raised its holdings in Inogen by 72.9% in the third quarter. Barclays PLC now owns 55,508 shares of the medical technology company's stock worth $539,000 after purchasing an additional 23,398 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in Inogen during the second quarter valued at $457,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Inogen by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company's stock valued at $5,377,000 after buying an additional 5,921 shares in the last quarter. 89.94% of the stock is currently owned by institutional investors.
Inogen Trading Down 0.5 %
Shares of INGN stock traded down $0.05 during trading hours on Monday, reaching $10.47. The company's stock had a trading volume of 149,232 shares, compared to its average volume of 148,305. Inogen has a one year low of $5.08 and a one year high of $13.33. The stock has a market capitalization of $249.37 million, a P/E ratio of -4.65 and a beta of 1.02. The firm's fifty day simple moving average is $9.52 and its 200 day simple moving average is $9.97.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on INGN shares. StockNews.com cut shares of Inogen from a "buy" rating to a "hold" rating in a report on Friday, December 20th. Needham & Company LLC reissued a "hold" rating on shares of Inogen in a report on Tuesday, January 14th.
View Our Latest Analysis on INGN
About Inogen
(
Get Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Featured Articles
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.